KURA Stock, Kura Oncology Inc. Information

Kura Oncology is a clinical stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor. The company s preclinical pipeline includes KO , an ERK inhibitor, and a menin MLL inhibitor program.